Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University • Indiana University
How would you treat a case of mixed histology NSCLC/SCLC that rapidly progresses following chemoradiation and durvalumab?
In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alternative makes more sense?
Answer from: Medical Oncologist at Academic Institution
In recent weeks, I have had several patients progressing on or immediately after stopping durvalumab following chemoradiation—a frustrating and difficult situation. In the patients I saw (without mixed histology), I discussed clinical trials of post-immune therapy progression. The particular q...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Car I/ etoposide/ atezo.